Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO-AF-AMI: DOAC Monotherapy vs Dual Antithrombotic Therapy in AF and AMI Patients Post-PCI
NCT07583784Recruiting
- Sponsor
- Chonnam National University Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rivaroxaban in Atrial fibrillation (AFib) and myocardial infarction (MI) (2 arms), sponsored by Chonnam National University Hospital. Primary endpoint: Net Adverse Clinical Events at 1 year. Started Aug 2026; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07583784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583784.